Acceptance and Commitment Therapy for Cancer-Related Psychological Symptoms
(ACTION Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests Acceptance and Commitment Therapy (ACT) to help cancer patients manage psychological symptoms and reduce the risk of opioid misuse. Participants attend six sessions with a psychologist to learn new strategies for handling difficult thoughts and feelings. This trial suits those with cancer who are on opioid therapy and concerned about substance use issues. As an unphased trial, it offers participants the chance to explore innovative therapy techniques that could enhance their quality of life.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should currently be on opioid therapy, so you may need to continue with that specific medication.
What prior data suggests that Acceptance & Commitment Therapy (ACT) for Cancer is safe?
Research has shown that Acceptance and Commitment Therapy (ACT) is generally safe for people with cancer. Studies have found that it can improve quality of life and help manage emotional challenges like anxiety and fear. Since ACT does not involve medication, it has fewer physical side effects than drug treatments. This therapy helps individuals accept their thoughts and feelings while encouraging actions that align with their values. Overall, patients have responded well to ACT, making it a promising option for managing emotional symptoms in cancer care.12345
Why are researchers excited about this trial?
Researchers are excited about Acceptance and Commitment Therapy (ACT) for cancer-related psychological symptoms because it offers a fresh approach to managing distress often associated with cancer. While standard treatments for psychological symptoms in cancer patients, such as medications and traditional talk therapy, focus on symptom reduction, ACT emphasizes acceptance of difficult emotions and commitment to personal values. This method can empower patients to live meaningful lives despite their cancer-related challenges. By shifting the focus from controlling negative thoughts to embracing them, ACT could provide a more flexible and enduring way for patients to cope with their symptoms.
What evidence suggests that Acceptance & Commitment Therapy (ACT) is effective for cancer-related psychological symptoms?
Research has shown that Acceptance and Commitment Therapy (ACT), which participants in this trial will receive, helps reduce stress, depression, and anxiety in cancer patients. Studies have found that it also improves quality of life and assists with emotional challenges. ACT specifically helps manage the fear of cancer returning and reduces the tendency to avoid problems. It has proven effective in easing symptoms of depression and overall stress. This makes ACT a promising approach to support emotional well-being for those undergoing cancer treatment.36789
Who Is on the Research Team?
Miryam Yusufov, PhD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults over 18 with any type of cancer, expected to live at least 6 more months, and who are on opioid therapy with a risk for substance use disorder. They should be able to do daily activities with little to no help and must understand English well enough for psychotherapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Acceptance & Commitment Therapy (ACT) for Cancer, involving 6 sessions with a licensed clinical psychologist
Follow-up
Participants are monitored for safety and effectiveness after treatment, including a post-study interview
What Are the Treatments Tested in This Trial?
Interventions
- Acceptance & Commitment Therapy (ACT) for Cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
National Cancer Institute (NCI)
Collaborator